Celldex Therapeutics
CLDX
CLDX
160 hedge funds and large institutions have $2.3B invested in Celldex Therapeutics in 2021 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 53 increasing their positions, 46 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
22% more funds holding
Funds holding: 131 → 160 (+29)
15% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 46
3.47% more ownership
Funds ownership: 89.03% → 92.5% (+3.5%)
Holders
160
Holding in Top 10
11
Calls
$85.9M
Puts
$69.9M
Top Buyers
| 1 | +$283M | |
| 2 | +$86.4M | |
| 3 | +$41.2M | |
| 4 |
CAC
Cowen and Company
New York
|
+$33.5M |
| 5 |
FAM
Fred Alger Management
New York
|
+$28.4M |
Top Sellers
| 1 | -$53M | |
| 2 | -$46.9M | |
| 3 | -$35.1M | |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$26.2M |
| 5 |
PA
Perceptive Advisors
New York
|
-$18.8M |